Purchase disclosed
David R. Epstein
Director
Common shares
- Reported value
- $42.85K
- Reported price
- $8.57 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
AgomAb Therapeutics NV
Last 30 daysInsiders bought $266.67K · 3 buyers, led by Tim Jasper Knotnerus (CEO) with $94.38K. No qualifying insider sales.
Showing the first 6 of 9 trades on this page.
Director
Common shares
Director
Common shares
Chief Financial Officer
Common shares
Chief Financial Officer
Common shares
Chief Financial Officer
Common shares
Chief Executive Officer
Common shares
Chief Executive Officer
Common shares
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common sharesPurchase | 5,000$8.57 / share | $42.85K | Oct 5Filed Oct 7 · 2d later | SEC filing |
| Director | Common sharesPurchase | 5,000$8.70 / share | $43.5K | Oct 6Filed Oct 7 · 1d later | SEC filing |
| Chief Financial Officer | Common sharesPurchase3 trades | 10,000avg $8.59 / share | $85.94K | Oct 6Filed Oct 7 · 1d later | 3 filings
|
| Chief Executive Officer | Common sharesPurchase | 6,000$8.48 / share | $50.88K | Oct 5Filed Oct 7 · 2d later | SEC filing |
| Chief Executive Officer | Common sharesPurchase | 5,000$8.70 / share | $43.5K | Oct 6Filed Oct 7 · 1d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units57,482Award · no purchase price | Non-cash award | Sep 11Filed Sep 15 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units56,328Award · no purchase price | Non-cash award | Sep 11Filed Sep 15 · 4d later | SEC filing |
This reflects the filings imported so far, not a complete trading history.
$266,670 of common-equity purchase value after transaction-age decay across 180 days.
3 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
3 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
A reporting-owner group bought on at least two distinct dates within the cluster window.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.